This is the substitution of the originator biologic with the biosimilar by the pharmacist. This is only appropriate for interchangeable biologics, or those that determined to produce the same effects when substituted for the originator product, without any additional risks. It is important that physician who prescribed the biologic is notified of the switch. This allows for the appropriate monitoring of a patient’s response to treatment, as well as close tracking of adverse events.